Expert Interview
A third look at Quviviq prescribing patterns since its FDA approval in May for treatment in adults with insomnia and how it compares to Merck's Belsomra and Eisai's Dayvigo.
Ticker(s): IDRSF, MRK, ESALYInstitution: SAS Specialists
- Manages 400 patients with narcolepsy and sees about 100 patients a month for insomnia
- dual board certified in internal medicine and sleep medicine.
- Sleep physician and CMO at the center for sleep medicine, managing OSA, CSA, Narcolepsy, RLS, RBD, etc. for adult and pediatric patients
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
